14. Acute myeloid leukemia consolidation

  1. Ross Pinkerton MB, BCh, BaO, MD Executive Director, Division of Oncology2,
  2. Ananth Shankar MD, FRCPCH Consultant in Paediatric and Adolescent Oncology3 and
  3. Katherine K. Matthay BA, MD Mildred V. Strouss Professor of Translational Oncology, Director, Pediatric Hematology-Oncology4
  1. Ananth Shankar

Published Online: 8 MAY 2013

DOI: 10.1002/9781118625309.ch14

Evidence-Based Pediatric Oncology

Evidence-Based Pediatric Oncology

How to Cite

Shankar, A. (2013) Acute myeloid leukemia consolidation, in Evidence-Based Pediatric Oncology (eds R. Pinkerton, A. Shankar and K. K. Matthay), John Wiley & Sons, Ltd, Oxford. doi: 10.1002/9781118625309.ch14

Editor Information

  1. 2

    Royal Children's Hospital, Children's Health Queensland, Brisbane, QLD, Australia

  2. 3

    University College London Hospitals NHS Foundation Trust London, UK

  3. 4

    Department of Pediatrics, UCSF School of Medicine and, UCSF Benioff Children's Hospital, San Francisco, CA, USA

Author Information

  1. University College London Hospitals NHS Foundation Trust, London, UK

Publication History

  1. Published Online: 8 MAY 2013
  2. Published Print: 20 MAY 2013

ISBN Information

Print ISBN: 9780470659649

Online ISBN: 9781118625309

SEARCH

Keywords:

  • acute myeloid leukemia (AML);
  • children;
  • consolidation chemotherapy;
  • cyclosporine;
  • drug efflux;
  • P-glycoprotein;
  • randomized study;
  • remission

Summary

The Pediatric Oncology Group (POG) trial 9421 was a prospective randomized study conducted between February 1995 and August 1999. The objective of the study is to determine whether interference of the P-glycoprotein mediated drug efflux mechanism by the addition of cyclosporine A (CsA) to consolidation chemotherapy in children with acute myeloid leukemia (AML) will prolong remission and improve overall outcome. This report only describes the primary results of the POG 9421 AML study. All patients with de novo AML of any subtype except FAB M3 subtype below 21 years of age were eligible for study enrollment. Randomization for both the induction and consolidation blocks (with or without CsA) was done at trial registration. It was concluded that the addition of cyclosporine A to consolidation chemotherapy did not prolong remission or improve overall survival in children with AML.